The Journal of Targeted Therapies in Cancer

The 5-year survival rate for patients with metastatic colorectal cancer (CRC) remains dismal. Liver metastases are a particularly common occurrence, developing in approximately half of all patients with colorectal cancer.
Cervical cancer screening based on identification of human papillomavirus (HPV) outperformed primary liquid cytology for detection of high-grade cervical intraepithelial neoplasia (CIN).
Dacomitinib has demonstrated potential as treatment for a subset of patients with recurrent squamous cell carcinoma of the head and neck (SCCHN).
The bromodomain inhibitor, OTX015, may have use in the treatment of hematologic malignancies, including acute leukemia and other hematologic malignancies that include lymphomas and multiple myeloma.
Allogeneic hematopoietic cell transplant (alloHCT) can be a mysterious process for patients and general oncologists.
For nearly 2 decades, researchers have been exploring B-cell–specific antigens in hopes of developing a new anticancer target that could surpass the success of CD20-targeting agents.
The concept of cancer immunotherapy— using the patient’s immune system to target and eradicate cancer—has evolved over more than a century of research.
JTT Articles
Androgen-Targeting Therapies Increasing in CRPC
NCCN Guidelines Include Obinutuzumab in CLL
CD19-Targeted Agents Continue to Show Positive Outcomes
External Resources

Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Internal Resources

Targeted Communications
Connect With Us:

About Us
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright TargetedOnc 2013
Intellisphere, LLC. All Rights Reserved.